Adagene Inc
ADAG2.630USD
+0.090+3.54%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
154.94MMarket Cap
LossP/E TTM
More Details of Adagene Inc Company
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Inc Info
Ticker SymbolADAG
Company nameAdagene Inc
IPO dateFeb 09, 2021
CEOLuo (Peter)
Number of employees138
Security typeDepository Receipt
Fiscal year-endFeb 09
Address4F, Building C14, No. 218, Xinghu Street
CitySUZHOU
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code- -
Phone8651287773632
Websitehttps://www.adagene.com/
Ticker SymbolADAG
IPO dateFeb 09, 2021
CEOLuo (Peter)
Company Executives of Adagene Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-46664.00%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Ms. Zhou Ling
Ms. Zhou Ling
Senior Director of Human Resources
Senior Director of Human Resources
--
--
Ms. Li Yan
Ms. Li Yan
Senior Vice President of Bioinformatics and Information Technology
Senior Vice President of Bioinformatics and Information Technology
--
--
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-46664.00%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
China (Mainland)
103.20K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Smith (Vincent C)
10.81%
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
Other
61.82%
Shareholders
Shareholders
Proportion
Smith (Vincent C)
10.81%
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
Other
61.82%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.58%
Investment Advisor
13.28%
Venture Capital
12.37%
Private Equity
8.03%
Corporation
1.93%
Hedge Fund
0.35%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.02%
Other
50.28%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
34
16.13M
33.64%
--
2025Q3
35
16.13M
34.15%
+1.22M
2025Q2
33
14.91M
35.61%
-1.53M
2025Q1
31
16.44M
41.65%
-3.18M
2024Q4
29
17.99M
26.58%
+3.27M
2024Q3
27
14.73M
28.57%
+3.50M
2024Q2
28
11.22M
29.45%
-1.07M
2024Q1
30
12.30M
23.60%
+1.88M
2023Q4
27
7.12M
26.44%
-1.20M
2023Q3
33
8.32M
27.49%
-14.57K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
General Atlantic LLC
3.78M
8.03%
-43.61K
-1.14%
Sep 30, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
WuXi AppTec Co, Ltd.
3.30M
7%
-685.45K
-17.21%
Sep 30, 2025
Panacea Venture
2.25M
4.77%
+2.25M
--
Sep 30, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Sep 30, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
